LY 274614

Known as: 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3alpha,4aalpha,6beta,8aalpha)-, LY-274614, LY274614 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2003
024619912003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
Although the mechanism of neuronal death in neurodegenerative diseases remains unknown, it has been hypothesized that relatively… (More)
Is this relevant?
1995
1995
The c-fos gene is expressed in the central nervous system (CNS) in response to neuronal stimuli. Induction of c-fos in certain… (More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Once daily s.c. administration of 5 mg/kg morphine, a mu-opioid agonist, or U50488H (U50), a kappa 1-opioid agonist, for 5 days… (More)
Is this relevant?
1994
1994
Administration of morphine-3-glucuronide (M3G) by the intracerebroventricular (i.c.v.) route in doses of 2-8 micrograms produced… (More)
Is this relevant?
1994
1994
Recent reports have demonstrated that the coadministration of morphine with an N-methyl-D-aspartate (NMDA) receptor antagonist… (More)
Is this relevant?
1994
1994
We previously showed that local striatal injections of malonate produce age-dependent excitotoxic lesions. In the present study… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
The ability of a competitive (LY274614; (+-)-6-phosphonomethyl-decahydroisoquinolin-3-carboxylic acid) and a noncompetitive… (More)
Is this relevant?
1993
1993
Recent studies show that N-methyl-D-aspartate (NMDA) antagonists protect against neurotoxicity induced by local injections of 1… (More)
Is this relevant?
1991
1991
Antagonists for the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor may have therapeutic potential as neuroprotectant… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 5
Is this relevant?
1991
1991
Pretreatment with the non-competitive NMDA (N-methyl-D-aspartate) antagonist MK801 (0.5, 1.0 mg/kg, s.c.) suppressed the… (More)
Is this relevant?